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The impact of the mutation status on the clinical course and the outcome of essential thrombocythemia (ET) patients has not yet been 
completely established. A total of 171 patients with diagnosed ET were tested and subsequently grouped, according to their mutation 
status – Janus Kinase 2 (JAK2) – 112 patients, calreticulin (CALR) – 36 patients, and thrombopoietin receptor (MPL) – 5 patients. Moreover, 
18 individuals were triple-negative (with non-mutated JAK2, CALR, and MPL). CALR-mutated patients preferentially were male, with higher 
platelets (PLT) counts (mean PLT = 1 002.3) and lower hemoglobin and hematocrit levels at the diagnosis, compared to the JAK2 (mean PLT 
= 933.6), MPL (mean PLT = 940.8) and triple-negative patients (mean PLT = 822.6) (p = 0.0035). The patients with CALR mutated, and the 
triple-negative ones had a lower risk of arterial and venous thrombosis (3% and 5.6% cases at the time of diagnosis, respectively) than the 
patients with JAK2 mutation (7.2%) (p = 0.9210). The overall survival rate did not differ statistically between the groups.
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Introduction
Essential thrombocythemia (ET) belongs to myeloproliferative 
neoplasms, with an incidence of 2.5 cases per 100,000 inhabitants, 
and is characterized by an increased risk of thrombosis. The molecular 
events leading to the development of ET are heterogeneous: 50–60% 
of the patients with ET carry a mutation in the Janus Kinase 2 (JAK2) 
gene [1], 3–7% of the patients’ mutation in the thrombopoietin receptor 
(MPL) gene, and about 20% in the calreticulin (CALR) gene [2, 3]. 
Thus, molecular confirmation of clonality that supports unambiguously 
diagnosis of ET is possible nowadays in 80–90% of the patients. The 
remaining 10% of patents are grouped into the triple-negative category 
[4, 5]. Molecular heterogeneity of ET may translate to a different clinical 
course of the disease. Some early reports suggest indeed that such 
differences exist. Here we present a cohort of 171 ET patients, treated 
at our institution, aiming at exploring the impact of the mutation status 
on the clinical course and features of the disease.
Material and methods
Patients
This study included a cohort of 171 patients, diagnosed and treated for 
ET at the University Clinical Centre at the Medical University of Gdansk 
between 2003 and 2014. The median follow-up was 4.7 years. The ET 
diagnosis was established according to the World Health Organization 
(WHO) criteria from 2008 [6]. Briefly, post-ET myelofibrosis (pET-MF) 
was diagnosed consistently with the criteria of the International 
Working Group of Myelofibrosis Research and Treatment [7]. The 
transformation into acute leukemia was defined by the WHO criteria [6]. 
Distribution of the risk for vascular complications was rated as follows: 
high risk at the age of ≥60 years old and/or previous thrombosis, low 
risk at the age of <60 years old, and/or no thrombosis history [8]. 
The prognostic score of thrombosis for essential thrombocythemia 
(IPSET thrombosis) score was not calculated due to a lack of patients’ 
cardiovascular risk factors data. Thrombotic events were defined as 
described by Barosi et al. [7]. The study protocol was approved by the 
Local Bioethics Committee at the Medical University of Gdansk and 
was carried out following the Declaration of Helsinki. Informed consent, 
concerning the use of the clinical data for research purposes, was 
obtained from all the participants.
Molecular analysis
The JAK2 V617F mutation status was assessed using the amplification 
refractory mutation system-polymerase chain reaction (ARMS-PCR) 
described by Jones et al. [9]. The patients with a non-mutated JAK2 
gene were further evaluated for CALR exon 9 and MPL exon 10 
mutations using high-resolution melting assay and Sanger sequencing 
[2, 10].
The patients with JAK2, CALR, and MPL mutations and the triple-
negative individuals were compared in terms of their demographic 
characteristics (sex distribution, age at diagnosis of ET), the clinical 
and laboratory features at the time of diagnosis, the clinical outcome 
(fibrotic or leukemic transformation), and the overall survival (OS).
* Corresponding author: Witold Prejzner, Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland, Debinki 7, 80-952 Gdańsk, Poland, phone: +48 50 4279722,  
   e-mail: wpre@gumed.edu.pl
231
A c t a  H a e m a t o l o g i c a  P o l o n i c a
The patients were treated according to the national recommendations. 
Cytoreductive therapy, using hydroxyurea was administered to the 
high-risk patients, which is with the incidence of arterial or venous 
thrombosis, elderly, and with comorbidities increasing the risk of 
a thrombotic event. Other treatment approaches included the use of 
anagrelide, busulfan, and interferon alfa.
Statistical analysis
Normal distributions of the continuous variables were verified by the 
Kolmogorov-Smirnov test, while their statistical characteristics were 
presented as arithmetic means, standard deviations (SDs), medians, 
and ranges. Statistical characteristics of the discrete variables were 
presented as numbers and percentages. A Student’s t-test or the 
Mann–Whitney U-test was used for intergroup comparisons of the 
continuous variables and distributions of the discrete variables. 
They were compared with the Pearson chi-square test or the Fisher 
exact test. The power and the direction of the relationships between 
the presence of mutation types, the demographic, and the clinical 
characteristics of the ET patients were determined based on the odds 
ratios (ORs) and their 95% confidence intervals (95% CI), calculated 
during logistic regression analysis. Survival curves were prepared 
with the use of the Kaplan-Meier method and compared with the 
log-rank test. All calculations were carried out using the Statistica10 
package (Stat Soft, USA) and the threshold of statistical significance 
was set at p ≤ 0.05.
Results
Distribution of the mutation status
The group of 171 ET patients includes 112 (65%) patients with 
a JAK2 mutation, 36 (21%) with CALR mutation, 5 (3%) with MPL 
mutation, and 18 (11%) triple-negative cases.
Overall, eight types of CALR mutations were detected. In the cohort 
of the 36 CALR-mutated patients, we found 14 (39%) individuals with 
a 52 bp deletion (c.1099-1150del – type 1) and 15 (41%) patients 
with a 5bp insertion (c.1154-1155insTTGTC – type 2). Seven (20%) 
patients were the carriers of one out of six other mutation types, with 
potentially three novel variants.
Demographic characteristics
The median age at diagnosis between patients with JAK2, CALR, 
and MPL mutations and of the triple-negative ones were 59, 53, 
66, and 52, respectively. The groups did not differ in terms of their 
age distribution, but there was a tendency toward lower age in the 
CALR and the triple-negative groups. There were more females 
(63%) than males in the whole ET group. The preponderance of 
females to males was preserved in all mutation subgroups except 
for CALR mutated patients with more males (56%) than females. 
The difference between the latter group and the JAK2 mutated group 
reached statistical significance. The demographic, as well as the 
clinical characteristics, are summarized in table I.
Laboratory parameters at the time of diagnosis
The laboratory parameters of all groups, according to the mutation 
type, are presented in table II. At the time of diagnosis, the JAK2-
mutated patients had mean hemoglobin (Hb) and hematocrit (Hct) 
levels (14.5 ± 1.5 g/dL and 44 ± 4.3 g/dL, respectively), compared to 
the other groups, and lower PLT counts when compared to the CALR 
and the triple-negative individuals; however, all Hb and Hct values 
remained within the normal range limits. There was a trend toward 
a higher white blood count (WBC) in the JAK2 group, in comparison 
to the CALR and the triple-negative groups (p = 0.1467).
Vascular complication risk and the observed incidence 
of vascular complication at diagnosis concerning the 
mutation status
More patients with high risk were observed in the JAK2 group 
(59.1%) than in the CALR and the triple-negative groups (36.7% 
and 27.8%, respectively). The difference in the distribution of the 
vascular complication risk between the JAK2, the CALR, and the 
triple-negative groups was statistically significant (p = 0.0264). The 
incidence of arterial or venous thrombotic events at the diagnosis 
was observed more often in the JAK2 group than in the other groups 
(7.2 vs. 5.6 and 3.0% in the triple-negative and the CALR group 
respectively), but the difference did not reach statistical significance 
(p = 0.9210). No incidence of arterial or venous thrombotic events 
was observed in the MPL group, possibly due to a low number of 
individuals (n = 5).
Treatment and the incidence of vascular complications 
concerning the mutation status and survival
During the follow-up period, arterial and venous thrombotic 
complications occurred in 7.2% of the patients from the JAK2 group, 
whereas in the CALR, the MPL, and the triple-negative groups no 
thrombotic complications were observed. The patients with CALR 
or MPL mutation as well as the triple-negative individuals had 
a lower risk of arterial or venous thrombosis than the patients with 
JAK2 mutation. Thrombosis-free survival was the highest in the 
CALR group. Bleeding complications were observed only in the 
CALR group (3.0%) during the follow-up. Transformation to pET-MF 
occurred in 2.9% of all patients during the follow-up, including two 
patients from the JAK2 group, two and one individuals from the CALR 
and the MPL groups, respectively. No transformation to pET-MF in 
the triple-negative group was observed. The difference between the 
groups was statistically significant (p = 0.0325).
The OS did not differ statistically among the three groups: the JAK2, 
the CALR, and the triple-negative. Due to a low number of MPL-
mutated patients (n = 5), the analysis was not performed in this group.
Clinical characteristic of the CALR subtypes
We compared clinical and laboratory parameters (Tab. III) between 
types 1 and 2 CALR subgroups. We found no statistical difference 
in the demographic characteristic (age and sex), the laboratory 
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parameters (Hb, Hct, WBC, and PLT count), the thrombotic 
incidences, the transformation risk, or in the OS.
Discussion
Discoveries of molecular changes in myeloproliferative neoplasms 
nowadays, allow confirmation of the diagnosis molecularly in 80–90% 
of ET subjects. Therefore, not only JAK2 but CALR and MPL mutation 
screening should be performed in every case of a suspected ET [11]. 
In our study, the molecularly defined ET patients accounted for 89% 
of the entire cohort. Similar data were presented by other authors 
[4], though in some studies the percentage of molecularly undefined 
ET patients was higher [12, 13]. Therefore, it is crucial to perform 
a precise differential diagnosis, to exclude secondary thrombocytosis 
in case of a lack of molecular markers. We should also be aware, that 
even in the case of a confirmed JAK2, CALR, or MPL mutations, other 
myeloid neoplasms (such as prefibrotic myelofibrosis and refractory 
anemia with ringed sideroblasts with marked thrombocytosis RARS-T) 
can mimic ET in their presentation. A trephine biopsy examination 
(different morphology of megakaryocytes) can help distinguish ET 
from other myeloid neoplasms [14]. Distribution of the JAK2, the 
CALR, the MPL, and the triple-negative patients in our cohort was 
similar to previous reports [4]. However, in the cohorts analyzed by 
Tefferi et al. [5] and Andrikovics et al. [15], there were more CALR-
mutated individuals (32 and 33%, respectively vs. 21%), and less 
JAK2-mutated patients than in our group. Whereas among the 1150 
ET patients, described by Finazzi et al [16], the CALR individuals 
accounted for only 16% of the entire group. In our CALR cohort, we 
found slightly more patients with type 2 mutation than those with type 
1 (41 vs. 39%). However, this observation is not consistent with other 
studies [5, 15], which reported the prevalence of a type 1 mutation 
at 50% of the CARL-mutated patients. Similarly to our studies, there 
was no difference between the subtypes 1 and 2, in terms of the 
demographic and the clinical characteristics. Further, population-
based studies are necessary to confirm the real mutation distribution 
in ET patients.
Whether the molecular changes could have an impact on the 
laboratory parameters and the clinical characteristics of ET patients, 
has remained a matter of debate ever since the CALR mutation 
discovery. Most researches state that CALR-mutated ET patients are 
characterized by younger age, higher PLT count, a lower incidence 
of thrombotic events, and a higher transformation rate to MF, in 








n = 18  (10.5%) p-value
Age at diagnosis
Mean (SD) 58.1 (15.1) 54.3 (14.9) 66.0 (11.3) 51.6 (11.6)
95% CI [55.3; 61.0] [49.2; 59.4] [48.0; 84.0] [45.8; 57.4]
Range (min–max) 23.0–88.0 24.0–82.0 54.0–78.0 30.0–74.0
Median 59.0 53.0 66.0 52.0 0.0948
Sex
Female 74 (66.1%) 16 (44.4%) 3 (60.0%) 14 (77.8%)
Male 38 (33.9%) 20 (55.6%) 2 (40.0%) 4 (22.2%) 0.0594
Symptoms at diagnosis
None 97 (87.4%) 30 (90.9%) 5 (100.0%) 16 (88.9%)
Thrombotic 5 (4.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Cardiovascular 3 (2.7%) 1 (3.0%) 0 (0.0%) 1 (5.6%)
Bleeding 3 (2.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Others 3 (2.7%) 2 (6.1%) 0 (0.0%) 1 (5.6%) 0.9210
Risk grade
High 65 (59.1%) 11 (36.7%) 2 (50.0%) 5 (27.8%)
Low 45 (40.9%) 19 (63.3%) 2 (50.0%) 13 (72.2%) 0.0264
Complications
None 101 (91.0%) 32 (97.0%) 4(100.0%) 16 (100.0%)
Thrombotic 7 (6.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Cardiovascular 1 (0.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Bleeding 0 (0.0%) 1 (3.0%) 0 (0.0%) 0 (0.0%)
Others 2 (1.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.7070
Transformation
Myelofibrotic 2 (1.8%) 2 (6.9%) 1 (25.0%) 0 (0.0%) 0.0325
Leukemic 16 (14.8%) 2 (6.5%) 1 (25.0%) 3 (17.6%) 0.5438
CALR – calreticulin; ET – essential thrombocythemia; JAK2 – Janus Kinase 2; MPL – thrombopoietin receptor
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comparison to JAK2-mutated patients [4, 5]. Our study showed that 
CALR-mutated patients are characterized by lower Hb and Hct levels, 
and there is a trend of a lower leucocyte count and a younger age at 
the diagnosis, compared to the JAK2-mutated subjects. We showed, 
that the CALR-mutated individuals are characterized by a higher PLT 
count in comparison to the JAK2-mutated patients. This observation 
is consistent with other studies already performed and suggests 
a difference in the biological effects of the mutation status in the JAK2 
and the CALR genes [15, 17]. It has been stated that a mutated JAK2 
promotes erythroid and granulocyte lineage, whereas a mutated 
CALR selectively promotes megakaryocytic proliferation [18].
Interestingly, the CALR-mutated patients, despite a higher PLT count, 
might be characterized by a lower rate of thrombotic events. This 
observation was also confirmed in our study group. Passamonti et al. 
[19] state that new risk assessment factors should be implemented 
in the risk stratification of ET patients. Moreover, the novel low-risk 
factors should include the presence of a CALR mutation. However, 
a study performed by Finazzi et al. [16] on 1150 ET patients showed 
that a CALR mutation does not have any significant impact on the 
IPSET thrombosis score. A low number of thrombotic events in 
CALR-mutated patients raises a question on the role of the PLT in 
the thrombotic events in ET individuals. More detailed studies are 
required regarding the role of the level and the activity of the von 
Willebrand factor, which could be more relevant for thrombosis 
occurrence than the PLT count [20].
Despite the clinical differences of the JAK2, the CALR, and the triple-
negative ET patients, we did not show any variation in the OS. The 
results presented by other authors are inconsistent. Klamfl et al. [2] 
showed a survival advantage for the CALR-mutated patients, but 






n = 5 Triple negative p-value
WBC
Mean (SD) 10.4 (6.3) 8.6 (2.6) 9.2 (5.5) 8.8 (2.7)
95% CI [9.2; 11.7] [7.6; 9.6] [0.4; 18.0] [7.4; 10.2]
Range (min–max) 3.0–63.0 4.4–14.1 5.0–17.3 2.0–13.5
Median 9.6 8.3 7.2 8.7 0.1467
Hb
Mean (SD) 14.5 (1.5) 13.7 (1.0) 12.8 (1.2) 13.5 (1.1)
95% CI [14.2; 14.8] [13.3; 14.0] [10.9; 14.7] [12.9; 14.0]
Range (min–max) 9.8–17.7 11.5–15.8 11.2–14.1 11.0–14.9 0.0139
Median 14.7 13.52 13.0 13.61 0.0034
Hct
Mean (SD) 44.0 (4.3) 41.0 (3.5) – 39.4 (2.5) 0.0002
95% CI [42.9; 45.1] [39.4; 42.5] – [37.9; 41.0] 0.0043
Range (min–max) 30.0–52.0 32.0–49.0 – 33.0–42.3
Median 44.0 41.0 – 39.0
PLT
Mean (SD) 933.6 (931.8) 1,002.3 (259.6) 940.8 (232.6) 822.6 (319.8) 0.0035
95% CI [757.5; 1 109.7] [911.7; 1 092.9] [652.0; 1 229.6] [663.6; 981.6] 0.0406
Range (min–max) 491.0–10,000.0 452.0–1,624.0 563.0–1,135.0 475.0–1,399.0
Median 787.5 1,024.0 1,006.0 652.0
CALR – calreticulin; ET – essential thrombocythemia; Hct – hematocrit; Hb – hemoglobin; JAK2 – Janus Kinase 2; PLT – platelets; MPL – thrombopoietin receptor; WBC – white blood count




52 bp deletion 
n = 14 p-value
WBC
Mean (SD) 8.2 (2.6) 9.1 (2.8)
95% CI [6.6; 9.7] [7.3; 10.9]
Range (min–max) 4.4–13.3 5.4–14.1
Median 7.5 8.6 0.7175
Hb
Mean (SD) 22.2 (30.9) 14.0 (1.1)
95% CI [3.5; 40.9] [13.3; 14.7]
Range (min–max) 12.3–125.0 12.4–15.8
Median 13.5 14.0 0.4265
Hct
Mean (SD) 42.1 (3.5) 40.8 (2.6)
95% CI [39.4; 44.7] [38.6; 43.0]
Range (min–max) 37.7–49.0 37.0–45.0
Median 42.0 40.5 0.5790
PLT
Mean (SD) 1,036.0 (313.2) 952.1 (233.9)
95% CI [855.2; 1,216.8] [817.0; 1,087.1]
Range (min–max) 452.0–1,624.0 662.0–1,415.0
Median 1,052.5 889.0 0.5035
CALR – calreticulin; Hct – hematocrit; Hb – hemoglobin; PLT – platelets; WBC – white 
blood count
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Tefferi et al. [5] as well as others [15] did not confirm this observation. 
The reason for inconsistent data could be the inadequate time of the 
follow-up.
The differences in the clinical courses of the JAK2-mutated and the 
CALR-mutated patients, especially in terms of the thrombosis risk 
and the myelofibrotic transformation rate, provides, in our opinion, 
a rationale for a different therapeutic approach to the high-risk patients. 
At present, two randomized trials, comparing hydroxyurea and 
anagrelide in ET patients have been performed. One randomized trial, 
comparing aspirin combined with either anagrelide or hydroxyurea, 
showed a lower incidence of fibrotic transformation and arterial 
thrombosis in the hydroxyurea treated patients [21]. The second 
one showed no difference between hydroxyurea and anagrelide 
treated patients, in terms of the fibrotic and the thrombosis rates [22] 
However, none of the studies compared the patients concerning the 
JAK2 and the CALR mutation status. We and others have proved 
that the mutation status defines the subtypes with substantially 
different clinical courses. The JAK2-mutated patients represent 
a different phenotype, with a higher risk of thrombosis and a lower 
risk of myelofibrotic transformation.
Conclusion
In conclusion, based on ours and other available studies, it can be 
stated that CALR-mutated patients display a distinct phenotype, 
compared to JAK2-mutated and MPL-mutated ET patients. 
Consequently, different therapeutic strategies should probably be 
implemented for these groups of patients, but further studies are 
necessary.
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